Table 1.
Patient demographics and baseline characteristics
| Placebo + WBRT (N = 102) | Veliparib 50 mg + WBRT (N = 103) | Veliparib 200 mg + WBRT (N = 102) | |
|---|---|---|---|
| Age, median (range) | 60 (41–86) | 60 (33–83) | 62 (39–81) |
| Sex, n (%) | |||
| Male | 56 (55) | 61 (59) | 66 (65) |
| Female | 46 (45) | 42 (41) | 36 (35) |
| Race, n (%) | |||
| White | 79 (78) | 85 (83) | 66 (65) |
| African American | 0 (0) | 2 (2) | 6 (6) |
| Asian | 22 (22) | 16 (16) | 28 (28) |
| Region, n (%)a | |||
| USA | 15 (15) | 12 (12) | 9 (9) |
| Non-USA | 87 (85) | 91 (88) | 93(91) |
| Histology at diagnosis, n (%) | |||
| Adenocarcinoma | 81 (80) | 86 (83) | 77 (75) |
| Squamous cell carcinoma | 11 (11) | 13 (13) | 17 (17) |
| Large cell carcinoma | 7 (7) | 0 (0) | 5 (5) |
| Other | 2 (2) | 4 (4) | 3 (3) |
| Missing | 1 | 0 | 0 |
| GPA score, n (%) | |||
| ≤2.5 | 91(89) | 91 (88) | 92 (90) |
| >2.5 | 11 (11) | 12 (12) | 10 (10) |
| Neurological symptoms (IVRS/IWR), n (%) | |||
| Asymptomatic | 53 (52) | 53 (52) | 53 (52) |
| Symptomatic | 59 (58) | 50 (49) | 49 (48) |
| KPS, n (%) | |||
| ≤80 | 39 (39) | 35 (34) | 39 (38) |
| >80 | 62 (61) | 68 (66) | 63 (62) |
| Missing | 1 | 0 | 0 |
| Number of brain mets (per central review), n (%) | |||
| 1 | 18 (18) | 22 (22) | 14 (14) |
| 2–3 | 22 (22) | 26 (26) | 29 (19) |
| >3 | 58 (59) | 53 (51) | 56 (57) |
| Unknown/missing | 4 | 2 | 3 |
| Extracranial mets, n (%) | |||
| Yes | 68 (67) | 76 (74) | 74 (73) |
| No | 33 (32) | 27 (26) | 28 (27) |
| Unknown | 1 | 0 | 0 |
| Smoking, n (%)b | |||
| Current | 25 (25) | 22 (21) | 20 (20) |
| Former | 52 (51) | 63 (61) | 58 (57) |
| Never | 24 (47) | 18 (17) | 23 (23) |
| EGFR, n (%)c | |||
| No | 34 (64) | 35 (71) | 35 (66) |
| Yes | 19 (36) | 14 (29) | 18 (34) |
| Unknown | 48 | 53 | 49 |
| Missing | 1 | 1 | 0 |
| ALK, n (%)c | |||
| No | 26 (100) | 24 (96) | 27 (96) |
| Yes | 0 (0) | 1 (4) | 1 (4) |
| Unknown | 75 | 77 | 74 |
| Missing | 1 | 1 | 0 |
Percentages based on known data
ALK anaplastic lymphoma kinase, EGFR epidermal growth factor receptor, GPA graded prognostic assessment, IVRS/IWR, interactive voice/web response system, KPS Karnofsky performance status, mets metastases, WBRT whole-brain radiation therapy
aOne patient in placebo arm is Native Hawaiian or Pacific islander
bMissing smoking status for one patient in placebo arm
cEGFR and ALK status was not required and the majority of sites did not report; percentages based on known data